The researchers noted that the Delta variant was the dominant strain in India during the study period, accounting for around 80% of all confirmed cases of COVID-19. (Photo PTI)

Coronavirus variants and vaccinations, active coronavirus cases in India today, November 24: Two doses of Covaxin are 50% effective against symptomatic COVID-19, according to the first real-world evaluation of the indigenous coronavirus vaccine in India published in The Lancet Infectious Diseases journal. The results of an interim study recently published in The Lancet showed that two doses of Covaxin, also known as BBV152, had 77.8 percent effectiveness against symptomatic illness and did not present any serious safety concerns.

The study also found that the effectiveness of the vaccine against symptomatic COVID-19 after two doses of Covaxin with the second dose given 14 days or more before undergoing an RT-PCR test was 50%. The adjusted vaccine efficacy of the first dose, estimated after seven and 21 days, was low, which is consistent with the performance of other preventive agents against the Delta variant, they said.

India reports 9,283 new cases and 10,949 recoveries

According to data shared by the Ministry of Health, India has reported 9,283 new cases, recorded 10,949 recoveries and recorded 437 deaths in the past 24 hours.

The number of active cases in the country stands at 1,11,481 – the lowest in 537 days.

118.44 crore vaccine doses have so far been administered in the country.

See also  Most Dutch people in favor of third corona jab | Inland

Here are the latest verified updates related to the coronavirus pandemic in India and around the world:

Leave a Reply

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.